• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2

    5/9/24 8:44:39 AM ET
    $AZN
    $EWTX
    $GSK
    $TARS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    As of May 9, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

    The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.  

    Here's the latest list of major overbought players in this sector.

    Zai Lab Limited (NASDAQ:ZLAB)

    • On May 8, Zai Lab posted better-than-expected quarterly results. “Our first quarter results demonstrate strong commercial execution and pipeline progress across our potential first- and best-in-class product portfolio,” said Dr. Samantha Du, Founder, Chairperson, and Chief Executive Officer of Zai Lab. The company's stock gained around 3% over the past month and has a 52-week high of $37.92.
    • RSI Value: 72.24                              
    • ZLAB Price Action: Shares of Zai Lab fell 0.7% to close at $16.57 on Wednesday.

    Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

    • On May 8, Tarsus Pharmaceuticals reported better-than-expected first-quarter financial results. “This was another tremendous quarter for Tarsus as we continued building a new category in eye care to serve millions of Demodex blepharitis patients with XDEMVY,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. The company's stock gained around 15% over the past five days and has a 52-week high of $40.40.
    • RSI Value: 74.27
    • TARS Price Action: Shares of Tarsus Pharmaceuticals fell 1.8% to close at $37.35 on Wednesday.

    Edgewise Therapeutics, Inc. (NASDAQ:EWTX)

    • On May 7, Edgewise Therapeutics named Arlene Morris to its Board of Directors. The company's stock gained around 29% over the past month and has a 52-week high of $21.60.
    • RSI Value: 74.25
    • EWTX Price Action: Shares of Edgewise Therapeutics fell 1.6% to close at $20.89 on Wednesday.

    GSK plc (NYSE:GSK)

    • On May 1, GSK reported better-than-expected first-quarter results and raised its 2024 core operating profit guidance. GSK expects 2024 adjusted EPS growth of 8% to 10%, up from the 6%-9% growth previously forecast. It expects 2024 sales to grow in the upper end of its 5% to 7% forecast range. The company's stock jumped around 10% over the past month and has a 52-week high is $44.33.
    • RSI Value: 72.85
    • GSK Price Action: Shares of GSK fell 0.02% to close at $44.14 on Wednesday.

    AstraZeneca PLC (NASDAQ:AZN)

    • AstraZeneca has declared a worldwide cessation of its COVID-19 vaccine, Vaxzevria, due to an "excess of updated vaccines." The company's stock jumped around 13% over the past month and has a 52-week high of $77.16.
    • RSI Value: 75.58
    • AZN Price Action: Shares of AstraZeneca climbed 0.9% to close at $76.97 on Wednesday.

    Read More: Roblox, Beyond Meat And 3 Stocks To Watch Heading Into Thursday

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $EWTX
    $GSK
    $TARS

    CompanyDatePrice TargetRatingAnalyst
    GSK plc
    $GSK
    1/27/2026Neutral
    Citigroup
    AstraZeneca PLC
    $AZN
    1/27/2026Buy
    Citigroup
    GSK plc
    $GSK
    1/6/2026Equal Weight → Underweight
    Barclays
    Tarsus Pharmaceuticals Inc.
    $TARS
    12/9/2025$100.00Overweight
    Barclays
    GSK plc
    $GSK
    11/25/2025Underperform → Neutral
    BofA Securities
    Tarsus Pharmaceuticals Inc.
    $TARS
    11/20/2025$100.00Outperform
    Mizuho
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    More analyst ratings

    $AZN
    $EWTX
    $GSK
    $TARS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on GlaxoSmithKline

    Citigroup initiated coverage of GlaxoSmithKline with a rating of Neutral

    1/27/26 8:46:26 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on AstraZeneca

    Citigroup initiated coverage of AstraZeneca with a rating of Buy

    1/27/26 8:43:14 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GlaxoSmithKline downgraded by Barclays

    Barclays downgraded GlaxoSmithKline from Equal Weight to Underweight

    1/6/26 11:51:57 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $EWTX
    $GSK
    $TARS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer

    IMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial IMFINZI plus IMJUDO combined with lenvatinib and transarterial chemoembolization (TACE) showed trend toward improved overall survival Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transarterial chemoembolization (TACE) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of prog

    4/2/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

    BOULDER, Colo., April 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on March 31, 2026, Edgewise granted inducement stock options to purchase a total of 72,000 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). Each

    4/1/26 8:00:00 AM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

    - Collaboration with Amgen to explore the clinical potential of Zai Lab's DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen's IMDELLTRA® - Amgen to sponsor and lead global Phase 1b study; Zai Lab to retain full ownership of zocilurtatug pelitecan Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ:AMGN) to evaluate Zai Lab's investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci, formerly ZL-1310), in combination with Amgen's IMDELLTRA® (tarlatamab-dlle), a DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy in patients with extensive-st

    4/1/26 7:30:00 AM ET
    $AMGN
    $ZLAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AZN
    $EWTX
    $GSK
    $TARS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fox Jonathan C bought $199,403 worth of shares (10,700 units at $18.64), increasing direct ownership by 82% to 23,702 units (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    11/13/25 6:04:59 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Smiley Joshua L bought $289,100 worth of American Depositary Shares (10,000 units at $28.91), increasing direct ownership by 13% to 86,604 units (SEC Form 4)

    4 - Zai Lab Ltd (0001704292) (Issuer)

    9/12/25 4:32:44 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thompson Peter A. bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

    4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)

    4/4/25 7:42:30 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $EWTX
    $GSK
    $TARS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Edmondson Frazor Titus Iii

    4 - Zai Lab Ltd (0001704292) (Issuer)

    4/3/26 5:58:53 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Smiley Joshua L

    4 - Zai Lab Ltd (0001704292) (Issuer)

    4/3/26 5:59:18 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Amado Rafael

    4 - Zai Lab Ltd (0001704292) (Issuer)

    4/3/26 5:57:35 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $EWTX
    $GSK
    $TARS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

    Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

    Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

    Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:29:16 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AZN
    $EWTX
    $GSK
    $TARS
    SEC Filings

    View All

    SEC Form 144 filed by Zai Lab Limited

    144 - Zai Lab Ltd (0001704292) (Subject)

    4/2/26 4:59:22 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    4/2/26 9:27:28 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    4/2/26 7:35:43 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $EWTX
    $GSK
    $TARS
    Financials

    Live finance-specific insights

    View All

    Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

    – Total revenues grew 17% y-o-y to $127.6 million for the fourth quarter of 2025 and 15% y-o-y to $460.2 million for the full-year 2025 – Zocilurtatug pelitecan (zoci) on track to become Zai Lab's first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026 – Advancing a differentiated global pipeline, including ZL-1503 (IL-13/IL-31Rα), ZL-6201 (LRRC15 ADC), ZL-1222 (PD-1/IL-12) and ZL-1311 (MUC17/CD3 TCE) – Key regional programs continue to advance, with KarXT approved in China and commercial launch preparations underway; pivotal data readouts for povetacicept in IgAN and elegrobart in TED expected in 2026

    2/26/26 7:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

    Generated full-year 2025 net product sales of XDEMVY® of $451.4 million, an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04 in ocular rosacea (OR) and plans to initiate a Phase 2 trial of TP-05 for Lyme disease prevention in Q2 2026 Management to host conference call today, February 23, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced financial results for the fourth quarter and full-year ended December 31, 2025, and recent business achievements.

    2/23/26 4:05:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

    IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing i

    2/17/26 4:30:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AZN
    $EWTX
    $GSK
    $TARS
    Leadership Updates

    Live Leadership Updates

    View All

    Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

    IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. "David is one of the most accomplished leaders in eye care, with a strong track record of translating innovation into global impact," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "His experience building some of the most successful franchises in our industry will be invaluable as we scale XDEMVY, advance our pipeline and position Tarsus for sustained growth. We are honored

    2/18/26 8:30:00 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $AZN
    $EWTX
    $GSK
    $TARS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

    SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)

    11/14/24 6:22:11 PM ET
    $EWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

    SC 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

    11/14/24 4:41:12 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tarsus Pharmaceuticals Inc.

    SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

    11/14/24 4:35:55 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care